The company was established in Jan. 2002, being a private high-tech bio-pharmaceutical enterprise jointly invested by three members of the Prof. Feng Baozhang family with a registered capital of RMB 300, 000. Now there are 8 people in the company, Prof. Feng included, and most of them are retired R&D personnel from the Institute of Hematology, Chinese Academy of Medical Science & Peking Union Medical College. Before retirement, Prof. Feng was engaged mainly in researches on etiopathogenesis of cancers, and through efforts in nearly ten years after retirement, he is able to elaborate etiopathogenesis and pathogeny of leukemia and other cancers. And he has developed 4 kinds of V-erbB serial products, effective rates of which are more than 80% in gene therapy and prevention of preleukemia(animals)and tumors in high incidence areas. In the recent years, V-erbB compounds have been developed for therapies of mid-advanced cancer patients. Now, the final step in research prior to clinic applications of the first patented product, the V-erbB injection, is underway.